www.panacos.com
Extended Medicinal Chemistry Contract Expands into Development Chemistry
Panacos Pharmaceuticals, Inc. a biotechnology company developing novel antiviral drugs for the treatment of Human Immunodeficiency Virus (HIV) infection and other major viral diseases, extended its ongoing discovery collaboration with Evotec into its fourth year. Applying its expertise in medicinal chemistry, Evotec has supported Panacos since 2004 in identifying novel compounds for treating viral infection.
Based on excellent progress, the work program has been extended and expanded to include Evotec's development chemistry services. This development support includes the scale-up of selected compounds for development studies and the optimization of compounds prior to their selection for clinical studies through experiments such as salt screens.
"Evotec's scientific expertise and project management skills are truly worldclass. Based on their excellent track record in moving compounds through discovery and into development, we decided to broaden the scope of our work with them. We are looking forward to continuing our productive relationship."
Dr Graham Allaway, Chief Operating Officer and President of Panacos